Company profile
Monoclonal antibodies for sale | ISCA Diagnostics
ISCA enables bench-to-bedside translation of hybridoma technology to the medical and veterinary sectors, providing easy access to highly specific monoclonal antibodies for research and diagnosis of human and animal mycoses.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0MDA2ODM4N2FkaXF6a2N4
Published 18 Oct 2024 12:02
Company registered at Companies House
1 Sep 2019 to 31 Jan 2021
ISCA Diagnostics, an innovative UK SME, is a leader in its field in developing innovative point-of-care (POC) diagnostic tests for fungal diseases. The proposed project seeks to develop a novel test for rapid diagnosis of invasive pulmonary aspergillosis (IPA), a life-threatening lung disease of immunocompromised humans which accounts for >300,000 deaths ...
